Latest From Affitech AS
Swiss biopharma company 4-Antibody AG has appointed Dr Robert F Burns as chief executive officer. Dr Burns will drive multi-target pharma collaborations, a key goal for the company following its deal with Boehringer Ingelheim last March, whereby it will develop fully human antibodies for a number of targets in a variety of disease indications. Dr Burns previously served as CEO at both human antibody therapeutics research company Affitech A/S and biotech company Celldex Therapeutics.
The Norwegian company Affitech, which recently merged with Pharmexa of Denmark through a reverse acquisition, has made unexpected changes to its leadership through the appointment of Dr Robert Burns as its new chief executive and Dr Alexander Duncan as senior vice-president of R&D.
Affitech has exclusively licensed global rights to develop and commercialise product candidates from Peregrine Pharmaceuticals' preclinical anti-VEGF antibody portfolio, including the fully human antibody r84, which was discovered by Affitech and jointly developed by the companies under an ongoing collaboration.
Pharmexa is to merge with the private Norwegian company Affitech in an all-stock transaction after several months of failing to find a buyer.
- Drug Discovery Tools
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Affitech AS
- Senior Management
Robert Burns, PhD, CEO
Hans Petter Tjeldflaat, Dir., Fin.
Michael Braunagel, PhD, Dir., Strategic Alliances & Lic.
Rathin C Das, PhD, SVP, Corp. Dev.
Alexander Duncan, PhD, SVP, R&D
- Contact Info
Phone: (47) 22 95 87 58
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.